SCHEMBL3228425

SCHEMBL3228425

CN1CCN(c2ccc3ccccc3c2)c2ccc(N3CCn4c(nnc4C(F)(F)F)C3)cc2C1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 2/20 0.45
SCN9A Q15858 1/20 0.40
HTR6 P50406 9/20 0.36
HTR1A P08908 4/20 0.36
HTR2A P28223 4/20 0.36
HTR7 P34969 3/20 0.36
DRD2 P14416 2/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HRH4 Q9H3N8 2/20 0.35
KCNH2 Q12809 1/20 0.34
MGAT2 Q10469 1/20 0.33
P2RY12 Q9H244 1/20 0.33
DRD3 P35462 2/20 0.33
HTR2C P28335 1/20 0.33
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3225628 0.92 SCN9A (0.42) HTR3ASCN9AHTR6CYP1A2CYP2D6
SCHEMBL3220899 0.87 MAOB (0.40) SCN9AHTR6HRH4
SCHEMBL3231981 0.87 DPP4 (0.38) SCN9AHTR2A
SCHEMBL3232100 0.87 SCN9A (0.40) SCN9A
SCHEMBL3229007 0.86 SCN9A (0.37) SCN9AHTR6CYP1A2CYP2D6CYP2C19
SCHEMBL3240198 0.86 DPP4 (0.39) SCN9AHTR6HTR2AHTR7DRD2
SCHEMBL3237513 0.86 SCN9A (0.40) SCN9A
SCHEMBL3231360 0.86 SCN9A (0.38) SCN9AHRH4P2RY12
SCHEMBL3231298 0.77 SCN9A (0.52) HTR3ASCN9AHTR6HTR1AHTR2A
SCHEMBL1248866 0.74 SLC6A4 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D HTR3A 30/4885SCN9A 795/4885HTR6 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.